促甲状腺激素抑制对分化型甲状腺癌患者生存结局的影响:系统综述与Meta分析
该系统综述与Meta分析纳入9项研究,评估中高危分化型甲状腺癌患者促甲状腺激素(TSH)抑制与不抑制对生存结局的影响。基于7项研究(3591例)的无进展生存、无病生存和无复发生存复合结局在两组间无显著差异(HR 0.75,95%CI 0.48-1.17,I²=76%);基于4项研究(3616例)的疾病特异性生存和总生存复合结局亦无显著差异(HR 0.69,95%CI 0.31-1.52,I²=88%)。基于2项研究(1294例)的心脏或骨骼不良事件复合结局在TSH抑制组显著更高(HR 1.82,95%CI 1.30-2.55,I²=0%)。作者认为TSH抑制可能不改善生存结局但可能增加继发并发症风险,证据有限且研究异质性大需谨慎解读。
要点
- 中高危DTC患者TSH抑制与不抑制相比,PFS/DFS/RLFS复合结局无显著差异(HR 0.75,95%CI 0.48-1.17)。
- DSS/OS复合结局在TSH抑制组与不抑制组间无显著差异(HR 0.69,95%CI 0.31-1.52)。
- TSH抑制组心脏或骨骼不良事件复合结局显著更高(HR 1.82,95%CI 1.30-2.55,I²=0%)。
核心结论
- 中高危分化型甲状腺癌患者中,TSH抑制可能不改善生存结局,但可能增加继发并发症风险,证据有限且研究异质性大,需谨慎解读。
研究设计与样本
- 系统综述与Meta分析,检索并筛选6369项研究,最终纳入9项研究,纳入随机对照试验、队列研究和病例对照研究,研究对象为≥18岁、按区域指南治疗且随访5年的中高危分化型甲状腺癌患者(PROSPERO #252396)。
- TSH抑制定义为低于正常参考范围或已知<0.5 mIU/L,所有结局和比较均表示为TSH抑制 versus TSH不抑制,采用随机效应模型计算汇总风险比(HR)和95%置信区间(CI)。
主要发现
- 基于7项研究(3591例患者),PFS、DFS和RLFS复合结局在TSH抑制组与不抑制组间无显著差异(HR 0.75,95%CI 0.48-1.17,I²=76%)。
- 基于4项研究(3616例患者),DSS和OS复合结局不支持TSH抑制(HR 0.69,95%CI 0.31-1.52,I²=88%)。
- 即使排除较低质量研究后,主要结局在TSH抑制组与不抑制组间仍无显著差异。
- 基于2项研究(1294例患者),心脏或骨骼不良事件复合结局在TSH抑制组显著更高(HR 1.82,95%CI 1.30-2.55,I²=0%)。
- 主要结局存在显著的研究异质性。
关键数值与推荐
- TSH抑制定义为低于正常参考范围,或已知<0.5 mIU/L。
- 主要结局为PFS、DFS和RLFS复合结局,以及DSS和OS复合结局;次要结局为心脏或骨骼不良事件复合结局。
临床怎么用
- 作者认为中高危分化型甲状腺癌的TSH抑制可能不改善生存结局但可能增加继发并发症风险,证据有限且研究异质性大需谨慎解读。
局限性
- 证据有限且研究异质性大,需谨慎解读研究结果。
- 主要结局存在显著的研究异质性(PFS/DFS/RLFS复合结局I²=76%,DSS/OS复合结局I²=88%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Long-term management of intermediate- and high-risk differentiated thyroid cancer (DTC) involves thyrotropin (TSH) suppression with thyroid hormone to prevent potential stimulation of TSH receptors on DTC cells, leading to tumor growth. However, the current guidelines recommending TSH suppression are based on low- to moderate-quality evidence. Methods: We performed a systematic review and meta-analysis of studies evaluating the role of TSH suppression in intermediate- and high-risk DTC patients (≥18 years) treated as per regional guideline-based therapy with a follow-up duration of 5 years (PROSPERO #252396). TSH suppression was defined as "below normal reference range" or, when known, <0.5 mIU/L. Primary outcome measures included (i) composite of progression-free survival (PFS), disease-free survival (DFS), and relapse-free survival (RLFS), and (ii) composite of disease-specific survival (DSS), and overall survival (OS). Secondary outcome included a composite of cardiac or skeletal adverse events. All outcomes and comparisons were represented as TSH suppression versus TSH nonsuppression. Randomized controlled trials, cohort studies, and case-control studies were included for analysis. Pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated using random-effects model. Results: Abstract screening was performed on 6,369 studies. After the exclusion of irrelevant studies and full-text screening, nine studies were selected for the final meta-analysis. Based on seven studies (3,591 patients), the composite outcome of PFS, DFS, and RLFS was not significantly different between TSH suppression and nonsuppression groups (HR: 0.75; 95% CI: 0.48-1.17; I2 = 76%). Similarly, a DSS and OS composite outcome assessment based on four studies (3,616 patients) did not favor TSH suppression (HR: 0.69; 95% CI: 0.31-1.52; I2 = 88%). Even after excluding studies of lower quality, the primary outcomes were not significantly different between the TSH suppression and nonsuppression cohorts. The secondary outcome, obtained from two studies (1,294 patients), was significantly higher in the TSH-suppressed groups (HR: 1.82; 95% CI: 1.30-2.55; I2 = 0%). Significant study heterogeneity was noted for primary outcomes. Conclusion: TSH suppression in intermediate- and high-risk DTC may not improve survival outcomes but may increase the risk of secondary complications. However, the limited evidence and study heterogeneity warrant cautious interpretation of our findings. Registration: PROSPERO #252396.
引用
- Gubbi S, Al-Jundi M, Foerster P, et al. The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. Thyroid. 2024. PMID: 38717947. doi:10.1089/thy.2023.0711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。